Tech Company Financing Transactions
Regado Biosciences Funding Round
On 12/17/2009, Regado Biosciences announced $40 million in Series D funding from Aurora Funds, Domain Associates and Quaker Partners.
Transaction Overview
Company Name
Announced On
12/17/2009
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series D
Investors
Proceeds Purpose
Proceeds from the financing will be used to continue the development of Regado's lead program in arterial thrombosis, REG1, with specific emphasis on the completion of the phase 2b (RADAR) trial currently underway. Additionally, the funding will support the completion of the ongoing phase 1 trial with the Company's second product candidate, REG2, focused on venous thrombosis as well as the identification of a clinical candidate therapeutic aptamer/active control agent pair in the REG-AP platelet adhesion/activation inhibitor discovery program.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
701 Gateway Blvd. 300
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Regado (NASDAQ: RGDO) is a spin-out of the Department of Surgery at Duke University Medical Center. Regado's technology enables the rational design of drug-antidote pairs against any target accessible to the bloodstream.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Laurent Fischer
Chief Financial Officer
Christopher Peetz
Chief Medical Officer
Eric Lefebvre
Chief Operating Officer
Helen Jenkins
Browse more venture capital transactions:
Prev: 12/17/2009: Bella Pictures venture capital transaction
Next: 12/17/2009: ShopperTrak venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs